Abstract
Introduction: An imbalance in the Autonomic Nervous System (ANS) is a central pathophysiologic mechanism in Heart Failure (HF) and has been a principal target of treatment in these patients. Traditional pharmacologic agents do not provide specific modulation of discrete arms of the ANS, while side effects may lead to poor tolerance. Technological advances have provided a series of invasive methods that may provide a focused effect on the ANS in selected patient groups. Renal denervation, initially targeted for patients with resistant hypertension, has given positive preliminary results in terms of heart structure and function. Baroreceptor stimulation also has ongoing research with respect to its efficacy and longer term effects in HF patients. Vagal nerve stimulation and spinal cord stimulation have limited data but represent novel treatments that target the hard to reach parasympathetic system.
Conclusion: The present review overviews the pathophysiologic basis, current preclinical and clinical data and future expectations of these promising treatments.
Keywords: Sympathetic nervous system, neuromodulation, renal denervation, baroreceptor stimulation, vagal nerve stimulation, spinal cord stimulation.
Graphical Abstract
Current Vascular Pharmacology
Title:Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?
Volume: 16 Issue: 1
Author(s): Costas Tsioufis*, Panayiotis Iliakis, Alexandros Kasiakogias, Dimitrios Konstantinidis, Dragan Lovic, Dimitrios Petras, Michalis Doumas, Eleftherios Tsiamis, Vasilios Papademetriou and Dimitrios Tousoulis
Affiliation:
- First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens,Greece
Keywords: Sympathetic nervous system, neuromodulation, renal denervation, baroreceptor stimulation, vagal nerve stimulation, spinal cord stimulation.
Abstract: Introduction: An imbalance in the Autonomic Nervous System (ANS) is a central pathophysiologic mechanism in Heart Failure (HF) and has been a principal target of treatment in these patients. Traditional pharmacologic agents do not provide specific modulation of discrete arms of the ANS, while side effects may lead to poor tolerance. Technological advances have provided a series of invasive methods that may provide a focused effect on the ANS in selected patient groups. Renal denervation, initially targeted for patients with resistant hypertension, has given positive preliminary results in terms of heart structure and function. Baroreceptor stimulation also has ongoing research with respect to its efficacy and longer term effects in HF patients. Vagal nerve stimulation and spinal cord stimulation have limited data but represent novel treatments that target the hard to reach parasympathetic system.
Conclusion: The present review overviews the pathophysiologic basis, current preclinical and clinical data and future expectations of these promising treatments.
Export Options
About this article
Cite this article as:
Tsioufis Costas*, Iliakis Panayiotis , Kasiakogias Alexandros, Konstantinidis Dimitrios, Lovic Dragan , Petras Dimitrios , Doumas Michalis , Tsiamis Eleftherios, Papademetriou Vasilios and Tousoulis Dimitrios, Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?, Current Vascular Pharmacology 2018; 16 (1) . https://dx.doi.org/10.2174/1570161115666170428124756
DOI https://dx.doi.org/10.2174/1570161115666170428124756 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blockade of Apoptosis by ACE Inhibitors and Angiotensin Receptor Antagonists
Current Pharmaceutical Design Dietary Fat and Hypertension: A Novel Approach Through the Proteolytic Regulatory Enzymes of the Renin-Angiotensin-System
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews Anesthetic Cardioprotection in Relation to Mitochondria: Basic Science
Current Pharmaceutical Design Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry Role of Polyphenol in Regulating Oxidative Stress, Inflammation, Fibrosis, and Apoptosis in Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties
Current Pharmaceutical Design Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging
Current Medicinal Chemistry Venoms and Poisonings during the Centuries: A Narrative Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart
Current Gene Therapy Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine Selective Peroxisome Proliferator-Activated Receptor-γ Modulation to Reduce Cardiovascular Risk in Patients with Insulin Resistance
Recent Patents on Cardiovascular Drug Discovery Fatty Liver and Ischemia/Reperfusion: Are there Drugs Able to Mitigate Injury?
Current Medicinal Chemistry State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases
Current Clinical Pharmacology Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry New Genetic Polymorphisms as an Epidemiological Factor of Arterial Hypertension in Patients with Hyposodical Diet
Current Hypertension Reviews Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology Phytosterols in Physiological Concentrations Target Multidrug Resistant Cancer Cells
Medicinal Chemistry A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews